Spicy secret to sharper gaming? nepalese pepper extract put to the test

NCT ID NCT07047105

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial investigates whether a supplement made from Nepalese pepper (Zanthoxylum armatum) can improve cognitive abilities like attention, memory, and decision-making in young competitive gamers aged 16 to 34. Participants take either a low or high dose of the extract, caffeine, or a placebo, then complete computer-based cognitive tests and gaming tasks. The goal is to see if the pepper extract outperforms placebo and how it compares to caffeine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nepalese pepper (Zanthoxylum armatum) extract in capsule form
What this could lead to
If it works, this could point toward a natural supplement to sharpen focus and reduce fatigue during competitive gaming.
What could go wrong
This is a small, early-stage trial in healthy young gamers, so results may not apply to other groups. The effects may be subtle or no better than caffeine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

57 people

The number who actually took part.

Started

Jun 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 34 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 16 to 34 years inclusive * Males and females * Self-report of good health * Usually a regular (at least once per week) player of competitive multiplayer games, (prospective participants will be asked to contact the researchers to discuss their gaming habits if uncertain that they meet the criteria). Exclusion Criteria: * Have any pre-existing medical condition/illness which will impact taking part in the study (i.e. participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance). * Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive treatments for female participants, and those taken 'as needed' in the treatment of asthma and hay fever. There may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening. * Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg); or have low blood pressure (systolic below 90 mm Hg or diastolic below 60 mm Hg) * Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2 * Are pregnant, seeking to become pregnant or lactating * Have learning and/or behavioural diagnoses such as dyslexia or ADHD * Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness) * Smoke tobacco or vape nicotine or use nicotine replacement products * Excessive caffeine intake (\> 500 mg per day). If participants consume energy drinks they will be asked to refrain from this for 24 hour prior to attending testing. * Have relevant food intolerances/sensitivities, including caffeine sensitivity. * Have taken antibiotics within the past 4 weeks * Have taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4-week supplement washout prior to participating and for the duration of the study on the proviso that the supplements they are taken are out of choice and not medically prescribed or advised) * Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken) * Are unable to complete all of the study assessments * Are currently participating in other clinical or nutrition intervention studies, or have done so in the past 4 weeks * Has been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months * Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months * Suffers from frequent migraines that require medication (more than or equal to 1 per month) * Sleep disorders or are taking sleep aid medication * Any known active infections * Are non-compliant with regards treatment consumption

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognition are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northumbria University - Brain Performance and Nutrition Research Centre

    Newcastle upon Tyne, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.